title: Translational In Vivo Models for Cardiovascular Diseases.
abstract: Cardiovascular diseases are still the first leading cause of death and morbidity in developed countries. Experimental cardiology research and preclinical drug development in cardiology call for appropriate and especially clinically relevant in vitro and in vivo studies. The use of animal models has contributed to expand our knowledge and our understanding of the underlying mechanisms and accordingly provided new approaches focused on the improvement of diagnostic and treatment strategies of various cardiac pathologies.Numerous animal models in different species as well as in small and large animals have been developed to address cardiovascular complications, including heart failure, pulmonary hypertension, and thrombotic diseases. However, a perfect model of heart failure or other indications that reproduces every aspect of the natural disease does not exist. The complexity and heterogeneity of cardiac diseases plus the influence of genetic and environmental factors limit to mirror a particular disease with a single experimental model.Thus, drug development in the field of cardiology is not only very challenging but also inspiring; therefore animal models should be selected that reflect as best as possible the disease being investigated. Given the wide range of animal models, reflecting critical features of the human pathophysiology available nowadays increases the likelihood of the translation to the patients. Furthermore, this knowledge and the increase of the predictive value of preclinical models help us to find more efficient and reliable solutions as well as better and innovative treatment strategies for cardiovascular diseases.
authors.affiliation: Bayer HealthCare AG, Cardiovascular I/III, Aprather Weg 18a, 42096, Wuppertal, Germany. Daniela.Fliegner@bayer.com.
authors.forename: Daniela
authors.initials: D
authors.lastname: Fliegner
authors.affiliation: Bayer HealthCare AG, Cardiovascular I/III, Aprather Weg 18a, 42096, Wuppertal, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Gerdes
authors.affiliation: Bayer HealthCare AG, Cardiovascular I/III, Aprather Weg 18a, 42096, Wuppertal, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Meding
authors.affiliation: Bayer HealthCare AG, Cardiovascular I/III, Aprather Weg 18a, 42096, Wuppertal, Germany.
authors.forename: Johannes-Peter
authors.initials: JP
authors.lastname: Stasch
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D057170:Translational Research, Biomedical
keywords: Animal models; Heart failure; Preclinical cardiology; Pulmonary hypertension; Thrombotic diseases; Translational research